We conducted a seroepidemiologic study during an outbreak of pandemic (H1N1) 2009 in a boarding school in England. Overall, 353 (17%) of students and staff completed a questionnaire and provided a serum sample. The attack rate was 40.5% and 34.1% for self-reported acute respiratory infection (ARI). Staff were less likely to be seropositive than students 13–15 years of age (staff 20–49 years, adjusted odds ratio [AOR] 0.30; >50 years AOR 0.20). Teachers were more likely to be seropositive than other staff (AOR 7.47, 95% confidence interval [CI] 2.31–24.2). Of seropositive persons, 44.6% (95% CI 36.2%–53.3%) did not report ARI. Conversely, of 141 with ARI and 63 with influenza-like illness, 45.8% (95% CI 37.0%–54.0%) and 30.2% (95% CI 19.2%–43.0%) had negative test results, respectively. A weak association was found between seropositivity and a prophylactic dose of antiviral agents (AOR 0.55, 95% CI 0.30–0.99); prophylactic antiviral agents lowered the odds of ARI by 50%.

In April 2009, an influenza A subtype H1N1 virus was isolated from persons in Mexico and the United States (1). This virus was responsible for the first influenza pandemic of the 21st century. The first cases of pandemic influenza A (H1N1) 2009 virus infection in the United Kingdom were reported on April 27, 2009, in a married couple who returned to Scotland after visiting Mexico (2). Several school outbreaks were reported soon after the virus was introduced into the United Kingdom (3,4), and influenza transmission in school settings was suggested as one of the primary drivers of the spread (5). In the United Kingdom, boarding schools have long been recognized as a good indicator population for the onset of seasonal influenza, leading to the establishment of Medical Officers of Schools Association surveillance scheme (6). In many schools, a high percentage of students and staff receive a seasonal influenza vaccine each year.

On May 27, 2009, a case of pandemic (H1N1) 2009 virus infection was confirmed in a student at a large boarding school in southeastern England from a respiratory sample submitted through the Medical Officers of Schools Association scheme. Public health authorities subsequently established that an ongoing outbreak of influenza-like illness (ILI) had occurred in this school in the 2 weeks before identification of the index case. Thirteen persons with onset of symptoms on or before that of the index case-patient also had positive test results, and health officials hypothesized that many unconfirmed clinical cases were also caused by infection with the emergent strain. This was the first recognized outbreak of the pandemic strain in a boarding school in the United Kingdom. In accordance with the Health Protection Agency’s (HPA) guidance at the time, postexposure antiviral prophylaxis was offered to all staff and students, and any person exhibiting symptoms of ILI was offered testing and prescribed a treatment dose of antiviral drugs. This outbreak and the public health control measures have been reported (7).
Influenza viruses are readily transmitted among residents in enclosed institutional settings (8). Challenge studies have suggested that one third of persons infected by influenza may be asymptomatic (9). In population studies, the proportion of asymptomatic influenza infections has been estimated at 50% (10), but whether similar proportions exist for pandemic (H1N1) 2009 is uncertain. Evidence exists regarding the effect of previous seasonal influenza vaccination on the acquisition of pandemic (H1N1) 2009 (11–15). This outbreak, with apparent transmission to many students before it was reported, provided opportunities to quantify rates of asymptomatic infection in a closed setting and study the association between exposure to the 2008–09 seasonal influenza vaccine and the use of antiviral agents with pandemic influenza (H1N1) 2009. We conducted a seroepidemiologic study in a boarding school population to describe the clinical spectrum of disease caused by the 2009 pandemic strain and to quantify the proportions of symptomatic and asymptomatic infections.

Methods

The study population was the 1,307 students and 825 staff attending and working at the boarding school, and all were invited to participate in the study. However, because the investigation occurred during an examination period, not all students and staff were present, and the exact number staying at the school during this period is unknown. All students were boarders; some staff members lived on the school grounds, and others lived outside.

Most of the outbreak cases occurred in May 2009. Study participants were asked to complete an online questionnaire and provide a single serum sample. Samples were collected from June 11 through June 26, the last day of term. Collection of data from the online questionnaire also began on June 11 and continued until October 15.

Serologic testing by hemagglutination inhibition (HI) was carried out as previously described (16–18) at the Centre for Infections, HPA, London, using egg-grown NIBRG122 (reverse genetics derivative of A/Eng/195/2009). Serum specimens were pretreated with receptor-destroying enzyme II (Denka Seiken Co., Ltd, Tokyo, Japan), 1:4 (vol/vol), at 37°C for 19 h, followed by heat inactivation at 56°C for 1 h. The assay was performed by mixing 25 μL of virus suspension (containing 4 hemagglutinating units) with an equal volume of receptor-destroying enzyme II–treated serum, followed by 1 h incubation at room temperature, after which 25 μL of 0.5% (vol/vol) turkey erythrocytes was added to each well. Serum specimens were tested in a 2-fold serial dilution series with an initial dilution of 1:8 and ending at 1:1,024. Titers were expressed as a reciprocal of the highest serum dilution that fully prevented hemagglutination. Serum specimens with no reactivity in the first dilution (<8; considered negative) were assigned a titer of 4; serum specimens that showed titers ≥1,024 were assigned a numerical value of 1,024 for statistical analysis. Serologic samples were excluded from statistical analyses if a person had reported illness within 14 days of sample collection because previous data suggested that 14–21 days is required for a measurable immune response (18).

The online questionnaire collected data on demographic characteristics: sex; age (age groups, years: 13–15, 16–18 [students]; 20–49, ≥50 [staff]); symptoms; severity (self-described as mild, moderate, severe); self-reported use of antiviral drugs for treatment or prophylaxis; and self-reported 2008–09 seasonal influenza vaccination. Results from these questionnaires were subsequently linked to the serology results. Questionnaires were excluded if the person reported being away from the school during the outbreak or if symptom onset occurred after June 10, 2009.

The outcomes of interest were seropositivity and clinical cases of acute respiratory infection (ARI). Seropositivity was defined as having an HI titer ≥32, i.e., a titer 4× the minimum detection limit. Similar definitions have been used in population-based serosurveys in other countries (19,20) and have been shown to be specific in identifying recent infection in children (21). For sensitivity analysis, we refitted the final logistic regression model (below) using an alternative cutoff value of 1:8, the minimum detection limit (22).

A clinical case of ARI was defined as a person reporting any one of the following respiratory symptoms; runny/blocked nose, sore throat, or cough. Those reporting ARI were further subcategorized into a more specific case definition, i.e., cases of ILI, defined as a person reporting ≥1 of the symptoms listed above and fever. Exposures of interest were the use of antiviral drugs, prescribed for prophylaxis or treatment, and seasonal trivalent influenza vaccine in the previous year (2008–09).

We estimated the proportion of asymptomatic cases by determining the proportion of the population with positive serologic test results but no symptoms of ARI. We also estimated the attack rate for those with ARI, ILI, and positive serologic test results and their distribution according to demographic variables.

Logistic regression models were constructed to estimate the independent association of antiviral drugs and seasonal influenza vaccine and the odds of being seropositive or having an ARI. Age was included in the model as a covariate; other linear predictors were included if model fit was significantly improved (likelihood-ratio [L-R] test p<0.05). Interaction between age group and antiviral agents for prophylaxis; and seasonal influenza vaccine was tested to determine whether these associations between predictors and seropositive status and ARI differed according to age group, and therefore according to student and staff categories. If interaction was observed (i.e., the
model was improved by including the interaction term), students and staff would be reported separately. A further model was also fitted for staff to investigate whether staff role and sex were associated with a seropositive status or ARI. Data analysis was carried out by using Stata version 11 (StataCorp LP, College Station, TX, USA).

Informed consent was sought from all students and their parents or guardians if students were <16 years old. Because this was a field epidemiology study conducted during an emerging pandemic and involved a novel virus with unknown clinical effects, HPA did not require formal ethical approval since any information gained was essential in illuminating the effects of the infection and indicating possible control measures.

Results

Sample Population

In total, 746 questionnaires were completed online, of which 695 (93.2%) met the inclusion criteria (Figure). This represented 35.9% of the 1,307 students and 27.4% of 825 staff who usually reside at the school. In total, 411 persons gave a serum sample and 353 (85.9%) were matched to a valid questionnaire (Figure). Of persons with a questionnaire and matched serologic test result, 216 were students and 137 staff, which accounts for 16.5% of the registered student population and 16.6% of the registered staff population; these 353 persons composed our final cohort (Figure).

Representativeness of Study Populations

The distribution of the study population by age, sex (staff only; all students were male), occupation (staff only), self-reported illness, history of seasonal influenza vaccine in the previous year, and the use of antiviral agents is shown in the online Appendix Table (www.cdc.gov/EID/content/17/9/100761-appT.htm). To determine whether our sample was representative of the total school population, we compared the final study population (questionnaire and matched serologic test result) to those who completed only the questionnaire (Figure). Of persons with a questionnaire and matched serologic test result, 216 were students and 137 staff, which accounts for 16.5% of the registered student population and 16.6% of the registered staff population; these 353 persons composed our final cohort (Figure).

Symptoms by Self-reported Illness and Serologic Test Results

For ARI, the attack rate was estimated at 35.9% (237/661, 95% confidence interval [CI] 32.2%–39.6%) or 16.6% (110/661, 95% CI 13.9%–19.7%) by using the definition for ILI (online Appendix Table). Of those who reported ARI and ILI, serologic test results were negative for 64/141 (45.4%, 95% CI 37.0%–54.0%) and 19/63 (30.2%, 95% CI 19.2%–43.0%) persons, respectively.

We found 143 seropositive persons, which gives an attack rate for infection of 40.5% (95% CI 35.3%–45.8%; Table 1). Of these 143 persons, 4 students did not answer the question relating to their illness status, and of the remaining 139 persons for whom illness history was available, 62 (44.6%, 95% CI 36.2%–53.3%) did not report ARI.

In crude analyses, persons who reported ARI were more likely to be seropositive (62/199, 54.2%; crude odds ratio [OR] 2.66, 95% CI 1.70–4.16) than those without illness (77/141, 29.9%). The odds of having serologic evidence of infection increased when the illness reported met the case definition for ILI (crude OR 4.44, 95% CI 2.45–8.02) (Table 1).

We also found an association between severity of reported illness and seropositivity. Overall, those reporting moderate or severe illness were more likely to be seropositive than those reporting mild illness (crude OR 2.21, 95% CI 1.10–4.41). We found no association between seropositivity and duration of illness (Table 1).
Association between Self-reported Illness, Infection, and Interventions

Overall, fewer students reported antiviral drug use than did staff (59.4% vs. 80.0%, p<0.001). Most of those taking a treatment dose were students (16/20, 80%) (Table 2). All students completed their prophylactic course of antiviral agents vs. 91% of staff. More students reported having had the 2008–09 trivalent seasonal influenza

| Variable                          | No. participants | No. (%) with positive serologic test result | Odds ratio (95% CI) |
|-----------------------------------|------------------|---------------------------------------------|---------------------|
| **Total**                         | 353              | 143 (40.5)                                  |                     |
| **Demographics**                  |                  |                                             |                     |
| **Category**                      |                  |                                             |                     |
| Students                          | 216              | 123 (56.9)                                  | 7.74 (4.48–13.35)   |
| Staff                             | 137              | 20 (14.6)                                   | 1                   |
| **Age group, y**                  |                  |                                             |                     |
| 13–15                             | 90               | 46 (51.1)                                   | 1                   |
| 16–18                             | 126              | 77 (61.1)                                   | 1.50 (0.87–2.60)    |
| 20–49                             | 71               | 12 (16.9)                                   | 0.19 (0.09–0.41)    |
| ≥50                               | 66               | 8 (12.1)                                    | 0.13 (0.06–0.31)    |
| **Sex, staff only†**              |                  |                                             |                     |
| F                                 | 71               | 5 (7.0)                                     | 1                   |
| M                                 | 66               | 15 (22.7)                                   | 3.88 (1.32–11.39)   |
| **Role, staff only‡**             |                  |                                             |                     |
| Nonteaching                       | 93               | 6 (6.5)                                     | 1                   |
| Teaching                          | 43               | 14 (32.6)                                   | 7.00 (2.46–19.90)   |
| **Clinical illness**              |                  |                                             |                     |
| **ARI**                           |                  |                                             |                     |
| No                                | 199              | 62 (31.2)                                   | 1                   |
| Yes                               | 141              | 77 (54.6)                                   | 2.66 (1.70–4.16)    |
| **ILI**                           |                  |                                             |                     |
| No                                | 277              | 95 (34.3)                                   | 1                   |
| Yes                               | 63               | 44 (69.8)                                   | 4.44 (2.45–8.02)    |
| **Severity, n = 153§**            |                  |                                             |                     |
| Mild                              | 81               | 38 (46.9)                                   | 1                   |
| Moderate and severe               | 59               | 39 (66.1)                                   | 2.21 (1.10–4.41)    |
| **Duration, d, n = 153§**         |                  |                                             |                     |
| 1–2                               | 14               | 6 (42.9)                                    | 1                   |
| 3–6                               | 52               | 27 (51.9)                                   | 1.44 (0.44–4.73)    |
| 7–10                              | 18               | 12 (66.7)                                   | 2.67 (0.63–11.28)   |
| >10                               | 23               | 14 (60.9)                                   | 2.07 (0.54–8.00)    |
| **Interventions**                 |                  |                                             |                     |
| Took antiviral drugs              |                  |                                             |                     |
| No                                | 96               | 48 (50)                                     | 1                   |
| Yes                               | 207              | 68 (32.9)                                   | 0.49 (0.30–0.80)    |
| **Use of antiviral drugs: PEP vs. treatment dose** | | | |
| No antiviral drugs                | 96               | 48 (50.0)                                   | 1                   |
| PEP dose only                     | 187              | 56 (30.0)                                   | 0.43 (0.26–0.71)    |
| Treatment dose                    | 20               | 12 (60)                                     | 1.5 (0.56–4.00)     |
| **Completion of PEP course of antiviral drugs¶** | | | |
| No antiviral drugs                | 96               | 48 (50.0)                                   | 1                   |
| Completed                         | 25               | 9 (36.0)                                    | 0.56 (0.23–1.40)    |
| Not completed                     | 159              | 45 (28.3)                                   | 0.39 (0.23–0.67)    |
| **Seasonal influenza vaccine**    |                  |                                             |                     |
| No                                | 105              | 29 (27.6)                                   | 1                   |
| Yes                               | 230              | 106 (46.1)                                  | 2.24 (1.36–3.69)    |

*Categories in which the response was missing or unknown are shown in the online Appendix Table (www.cdc.gov/EID/content/17/9/100761-appT.htm).
CI, confidence interval; ARI, acute respiratory infection; ILI, influenza-like illness; PEP, postexposure prophylaxis.
†All students were male.
‡1 staff member was not included in the analysis because his occupation was unknown.
§Of those that self-reported ARI.
¶Excluding those who reported taking the treatment dose of antiviral drugs.
vaccine than staff (81.1% vs. 50.0%; p < 0.0001 in the matched sample).

In logistic regression models for ARI and serologic status (Table 3), including age group, significantly improved the fit of the models (both L-R tests p < 0.001 compared models, including only antiviral drug use and vaccination status). No evidence of effect modification was found between age group and antiviral drugs or vaccination status for either outcome (L-R test p = 0.87 and p = 0.77, respectively). Therefore, stratified models were not fitted for staff and students.

Staff in the age groups 20–49 years and ≥50 years (adjusted ORs [AORs] 0.30 [95% CI 0.12–0.73] and 0.20 [95% CI 0.08–0.53], respectively) were less likely to have positive serologic test results than students 13–15 years of age (Table 3). This effect was not observed when ARI was used as the outcome. Weak evidence suggests that those 16–18 years of age were more likely to be seropositive and have ARI than those 13–15 years of age (AOR 1.85 [95% CI 0.95–3.60] and 1.57 [95% CI 0.98–2.53], respectively).

Although odds of seropositivity did not increase significantly with receipt of 2008–09 seasonal influenza vaccine (p = 0.10), the point estimate was >1. Likewise, the point estimate of the AOR for the association between taking a prophylactic dose of antiviral agents and seropositivity was <1 (p = 0.045). In a similar model, with ARI as the outcome of interest, having received a prophylactic dose significantly reduced the odds of ARI (AOR 0.41, 95% CI 0.27–0.61).

For the staff-only models (Table 4), staff role improved the model that predicted serologic results and ARI (L-R test p < 0.001 and 0.01, respectively). After staff role was taken into account, including sex as a factor did not improve the accuracy of either model and was therefore not included.

For the multivariable logistic regression model, which included only staff, age groups, staff role, exposure to prophylactic course of antiviral agents, and having received the 2008–09 seasonal influenza vaccine were considered. Teachers were more likely be seropositive than other staff members (AOR 7.47, 95% CI 2.31–24.18), and no
association was found between seropositivity outcome and age, taking the prophylactic dose of antiviral drugs, or receiving the influenza vaccine (Table 4).

When the final logistic models were refitted by using the minimum detection limit (≥1:8) to define seropositive status, this change made little difference to the point estimates of the ORs for antiviral drug use, age group, or seasonal vaccine. For the staff-only model, using a cutoff value ≥1:8 changed the point estimates for taking antiviral agents and age groups (≥50 vs. 20–49 years) to >1; however, neither linear predictor was significantly associated with the outcome with either cutoff value.

**Discussion**

This study describes the seroprevalence of infection with the pandemic (H1N1) 2009 virus in an enclosed institutional environment and provides evidence of widespread infection among both students and staff before the outbreak became evident to public health authorities. Attack rates for infection were estimated as 40.5% by serologic testing and as 34.1% by clinical illness (ARI). Attack rates. Selection bias in the serology study subsample is also evident in the ORs for the 2008–09 seasonal influenza vaccine, for which the ORs were different, according to whether a serologic or clinical outcome was used, because the effect would be expected to be in the same direction. In addition, vaccination status was self-reported and could not be validated against official records, and we did not collect dates that antiviral drugs were used from each person.

We used a cutoff value of an HI titer ≥32 to indicate recent seroconversion. A previous study (18) has indicated that cross-reactive antibody to pandemic (H1N1) 2009 virus was prevalent in England’s population before the pandemic and that seroprevalence was strongly associated with age. In addition, a high proportion of children at the school provided a serum sample. Because the study was conducted during an examination period, and some students and staff were absent, the size of the population from which the study sample was drawn is not known. However, because this was definitely less than the registered population, our response rate estimation was conservative. The distribution of our study population was not significantly different from the school’s population in age, school year, and sex (among teachers). However, the subsample of persons who provided a serum sample likely were not representative of persons who answered the questionnaire. For example, persons who provided a serum sample were more likely to have reported an ARI than persons who responded to the questionnaire only. This resulted in the overestimation of attack rates. Selection bias in the serology study subsample is also evident in the ORs for the 2008–09 seasonal influenza vaccine, for which the ORs were different, according to whether a serologic or clinical outcome was used, because the effect would be expected to be in the same direction. In addition, vaccination status was self-reported and could not be validated against official records, and we did not collect dates that antiviral drugs were used from each person.

We used a cutoff value of an HI titer ≥32 to indicate recent seroconversion. A previous study (18) has indicated that cross-reactive antibody to pandemic (H1N1) 2009 virus was prevalent in England’s population before the pandemic and that seroprevalence was strongly associated with age. In addition, a high proportion of children at the school

**Table 3. Multivariable analysis of all study participants in relation to having ARI or serology-confirmed infection during outbreak of pandemic (H1N1) 2009, England**

| Variable                      | AOR (95% CI) for ARI in questionnaire sample | AOR (95% CI) for positive test result in matched sample |
|-------------------------------|---------------------------------------------|-------------------------------------------------------|
| Age group, y                  |                                             |                                                       |
| 13–15                         | 1                                           | 1                                                     |
| 16–18                         | 1.57 (0.98–2.53)                             | 1.85 (0.95–3.60)                                       |
| 20–49                         | 1.00 (0.53–1.89)                             | 0.30 (0.12–0.73)                                       |
| ≥50                           | 0.66 (0.32–1.34)                             | 0.20 (0.08–0.53)                                       |
| Took antiviral drugs for PEP† |                                             |                                                       |
| No                            | 1                                           | 1                                                     |
| Yes                           | 0.41 (0.27–0.61)                             | 0.55 (0.30–0.99)                                       |
| Seasonal Influenza vaccine    |                                             |                                                       |
| No                            | 1                                           | 1                                                     |
| Yes                           | 1.01 (0.63–1.62)                             | 1.81 (0.91–3.59)                                       |

*For ARI, n = 654 who completed questionnaires; for serology-confirmed infection, n = 333 who completed questionnaires and had a matched serology sample. ARI, acute respiratory infection; AOR, adjusted odds ratio; CI, confidence interval; PEP, postexposure prophylaxis.
†Persons who reported taking treatment dose of antiviral agents were excluded.

**Table 4. Multivariable analysis of staff only in relation to having ARI or serology-confirmed infection during outbreak of pandemic (H1N1) 2009, England**

| Variable                      | AOR (95% CI) for ARI in questionnaire sample | AOR (95% CI) for positive test result in matched sample |
|-------------------------------|---------------------------------------------|-------------------------------------------------------|
| Age group, y                  |                                             |                                                       |
| 20–49                         | 1                                           | 1                                                     |
| ≥50                           | 0.71 (0.32–1.57)                             | 0.91 (0.26–3.14)                                       |
| Role                          |                                             |                                                       |
| Nonteaching                   | 1                                           | 1                                                     |
| Teaching                      | 1.18 (0.56–2.52)                             | 7.47 (2.31–24.18)                                      |
| Took antiviral drugs for PEP† |                                             |                                                       |
| No                            | 1                                           | 1                                                     |
| Yes                           | 0.34 (0.15–0.77)                             | 0.66 (0.18–2.39)                                       |
| Seasonal influenza vaccine    |                                             |                                                       |
| No                            | 1                                           | 1                                                     |
| Yes                           | 2.36 (0.69–8.11)                             | 2.36 (0.69–8.11)                                       |

*For ARI, n = 226. ARI, acute respiratory infection; AOR, adjusted odds ratio; CI, confidence interval; PEP, postexposure prophylaxis.
†Persons who reported taking the treatment dose of antiviral drugs were excluded.
had been vaccinated and were therefore unlikely to be representative of children in England. Conflicting evidence exists regarding the effect of prior trivalent influenza vaccination on cross-reactive titers for pandemic (H1N1) 2009 virus in persons <55 years of age (21,24). Therefore, some misclassification of cases (persons who seroconverted as a result of exposure to pandemic [H1N1] 2009 virus) likely occurred, leading to possible overestimation of the proportion of asymptomatic patients. However, the proportion of misclassified seropositive persons is likely small, particularly among children. Ideally, paired samples (collected before and after the outbreak) would have been able to measure seroconversion; however, this opportunity was not available.

These results highlight the fact that, depending on the virulence and transmissibility of an emerging influenza pandemic virus, extensive transmission may occur in a closed setting and thus by implication in the community over and above the observed clinical disease. This finding has notable implications for predicting the future course of a pandemic because the subsequent pool of those susceptible after initial transmission will diminish (18). Current policy in closed settings in the United Kingdom is to isolate or place symptomatic persons in cohorts after diagnosis to minimize the risk for onward transmission. If a substantial proportion of mildly symptomatic or even possibly asymptomatic persons were able to transmit infection, current policy would be of limited value. First, infection may be widespread within an institution long before it becomes apparent to public health authorities; second, a large number of persons may be infected but asymptomatic or mildly symptomatic when the first case is diagnosed. Although conclusions can be drawn from this study that rapid transmission of influenza occurred in this environment and that infection may not always produce symptoms, the evidence of transmission of the influenza virus by asymptomatic persons remains scant (25).

Our findings indicate that the use of prophylactic antiviral agents lowers the odds of an ARI by ≈50% but has no effect on reducing the odds of serologic infection. Several interpretations of these findings are possible; for example, while prophylactic antiviral agents might not reduce the risk for infection, they could protect from clinical disease. Published evidence from the occurrence of seasonal influenza has indicated that timely administration of prophylactic antiviral agents to close contacts of infected persons reduces the risk for disease (26). However, our results should be viewed with caution. First, the serology sample was a much smaller subset of the questionnaire survey respondents, and the results for a serologic outcome indicate a lack of power. Thus, the effectiveness of antiviral prophylaxis would be underestimated. Also, the low specificity of the case definition for ARIs could lead to an overestimation of the effect on clinical disease.

The association between self-reported illness and severity of illness with an increasing likelihood of seropositivity suggests that even in facilities with a limited diagnostic capacity, simple definitions of ILI may be a more specific indicator of the true presence of infection in communities in which a proven outbreak is under way. Fever was an essential part of the clinical case criteria for testing in the United Kingdom, in contrast to the United States, where the clinical criteria were either a “respiratory illness” (recent onset of ≥2 of the following: rhinorrhea/nasal congestion, sore throat, cough, fever or feverishness) or an ILI (fever >37.8°C [100°F], plus cough or sore throat). This study has demonstrated evidence of widespread infection with pandemic (H1N1) 2009 virus in a closed setting, with a substantial proportion of asymptomatic persons. Although the study highlights the difficulties of obtaining a large representative sample from a boarding school population during a pandemic influenza outbreak, it also illustrates the value of such rapid field epidemiologic investigations in understanding an emergent threat. This was particularly relevant during the emergence of pandemic (H1N1) 2009 virus at a time when its pathogenicity was uncertain and the benefit of using antiviral agents for postexposure prophylaxis was unclear. The results of this seroepidemiologic study in an outbreak setting during the pandemic of novel pandemic (H1N1) 2009 highlight the need for health authorities to agree on protocols for similar investigations during future pandemics.

Acknowledgments

We acknowledge the support of colleagues in this investigation: Peter Hawtin and the team at the HPA Southampton Laboratory, Josh Bruce, Anne Maduma-Butshe, and Gail Fairbairn.

Ms Johnson was a senior epidemiological scientist at the HPA South East Regional Unit, London, at the time of this study. Her responsibilities included routine outbreak investigations and surveillance of communicable disease. Her research interests focus on intervention epidemiology and the structural determinants of the distribution of communicable diseases.

References

1. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children—southern California, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1–4.
2. Health Protection Agency and Health Protection Scotland New Influenza A(H1N1) Investigation Teams. Epidemiology of new influenza A (H1N1) in the United Kingdom, April–May 2009. Euro Surveill. 2009;14:pii:19213.
3. Kar-Purkayastha I, Ingram C, Maguire H, Roche A. The importance of school and social activities in the transmission of influenza A(H1N1)v: England, April–June 2009. Euro Surveill. 2009;14 pii: p19311.

4. Health Protection Agency West Midlands H1N1v Investigation Team. Preliminary descriptive epidemiology of a large school outbreak of influenza A(H1N1)v in the West Midlands, United Kingdom, May 2009. Euro Surveill. 2009;14 pii: p19264.

5. Sypsa V, Hatzakis A. School closure is currently the main strategy to mitigate influenza A(H1N1)v: a modeling study. Euro Surveill. 2009;14 pii: p19240.

6. Medical Officers of Schools Association. The MOSA handbook of school health, 18th ed. Stoke-on-Trent (UK): Trentham Books, Ltd; 1998.

7. Smith A, Coles S, Johnson S, Saldana L, Ihekweazu C, O’Moore E. Medical of school health, 18th ed. Stoke-on-Trent (UK): Trentham Books, Ltd; 1998.

8. Garcia-Garcia L, Valdespino-Gómez JL, Lazcano-Ponce E, Jimenez-Muñiz C, González-Leon M, et al. Infection and death from influenza A(H1N1) virus in Mexico: a retrospective analysis. Lancet. 2009;374:2072–9. doi:10.1016/S0140-6736(09)61638-X

15. Effectiveness of 2008–09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1)—United States, May–June 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1241–5.

16. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37:937–43.

17. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009;361:2424–35. doi:10.1056/NEJMoa0907650

18. Miller E, Hoschler K, Harald P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375:1100–8. doi:10.1016/S0140-6736(09)62126-7

19. Wu JT, Ma ES, Lee CK, Chu DK, Ho PL, Shen AL, et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis. 2010;51:1184–91. doi:10.1086/656740

20. Bandaranayake D, Huang QS, Bissieo A, Wood T, Mackereth G, Baker MG, et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS ONE. 2010;5:e13211. doi:10.1371/journal.pone.0013211

21. Harald P, Andrews NJ, Hoschler K, Stanford E, Baguelin M, Waigt PA. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza AH1N1 2009. Health Technol Assess. 2010;14:115–92.

22. Zimmer SM, Crevar CJ, Carter DM, Stark JH, Giles BM, Zimmerman RK, et al. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS ONE. 2010;5:e11601. doi:10.1371/journal.pone.0011601

23. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am J Epidemiol. 1982;115:736–51.

24. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52. doi:10.1056/NEJ Moa0906453

25. Eccles R. Asymptomatic spread of flu is not proved. BMJ. 2005;331:1145. doi:10.1136/bmj.331.7525.1145

26. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassan N, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748–54. doi:10.1001/jama.285.6.748

Address for correspondence: Chikwe Ihekweazu, Health Protection Agency, Regional Epidemiological Unit, 151 Buckingham Palace Rd, London SW1W 9Z, UK; email: chikwe.ihekweazu@hpa.org.uk